Pneumocystis jirovecii pneumonia in a human immunodeficiency virus-infected patient with G6PD deficiency-successful treatment with anidulafungin.
We reported a HIV-infected patient, diagnosed as PJP with G6PD deficiency. Pneumocystis jiroveci pneumonia (PJP) is the most common opportunistic infection in subjects with human immunodeficiency virus (HIV) infection. Trimethoprim-sulfamethoxazole (TMP-SMX) is the first line regimen for Pneumocystis jirovecii pneumonia. However, patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency should avoid this agent to prevent hemolysis. Although there is evidence of echinocandins used successfully in animal studies, and few articles describing the clinical use of caspofungin, the clinical experience of anidulafungin as an alternative regimen to the treatment of PJP is rare in the HIV-infected patients. The patient was successfully treated with anidulafungin for 3 weeks and was led to a successful outcome.